High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.

View in: PubMed

subject areas

Administration, Oral
Adult
Age Factors
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Dexamethasone
Disease-Free Survival
Doxorubicin
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Lymphoma, Mantle-Cell
Male
Middle Aged
Rituximab
Treatment Outcome
Vincristine

authors with profiles

RUTH L KATZ
BARRY I SAMUELS
FREDRICK B HAGEMEISTER
MARIA A RODRIGUEZ
LUIS E FAYAD
L JEFFREY MEDEIROS
LUHUA WANG
FELIPE SAMANIEGO